Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q2 FY2023 Earnings Presentation
35 slides from Piramal Pharma's earnings presentation, November 2022
Slide 1: Piramal Pharma Limited Q2 & H1 FY2023 Results
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Piramal Pharma Limited Q2 & H1 FY2023 Results November 2022
Slide 2: Disclaimer
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 2 Disclaimer Except for the historical information contained herein, statements in this presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'ma
Slide 3: Three-Pronged Business Model with Market Leading Positions
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 3 Three-Pronged Business Model with Market Leading Positions Contract Development and Manufacturing Organisation Complex Hospital Generics India Consumer Healthcare (CDMO) (CHG) (ICH) 13 CDMO sites across North America, Europe and I
Slide 4: Track Record of Consistent Performance
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 4 Track Record of Consistent Performance Healthy performance over a sustained period of time (In INR Crore) Annual Revenue EBITDA Margin Diversified revenue mix Best-in-Class Quality Track Record* 7% 11% 14% 14% 15% 17% 18% 21% 26%
Slide 5: Piramal Pharma - Demerged and listed on BSE and NSE
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 5 Piramal Pharma - Demerged and listed on BSE and NSE Demerger and simplification of corporate structure Piramal Pharma Ltd. (PPL) demerged from Piramal Enterprise Ltd. It listed on BSE and NSE on 19th October 2022 Aligned interests
Slide 6: Piramal Pharma Sustainability Report FY2021-22
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 6 Piramal Pharma Sustainability Report FY2021-22 Sustainability Report FY2021-22 Piramal Pharma unveiled its Sustainability Report FY21–22, articulating its ESG journey to accelerate the pace of integrating sustainable practices T
Slide 7: Key Performance Highlights of Q2 and H1 FY2023
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 7 Key Performance Highlights of Q2 and H1 FY2023 Financials data used on all slides ahead do not include non-common control transactions and hence YoY financial are not strictly comparable. All data used in charts are based on repor
Slide 8: Key Performance Highlights of Q2 and H1 FY2023
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 8 Key Performance Highlights of Q2 and H1 FY2023 Q2 FY2023 H1 FY2023 Historically, H2 has outperformed H1 (In INR Crore) % of Full Year Revenue Revenue EBITDA Margin 54 57 55 14% 13% 13% 12%* 46 43 45 3,202 FY20 FY21 FY22 2,889 H1 S
Slide 9: CDMO Business (Piramal Pharma Solutions)
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 9 CDMO Business (Piramal Pharma Solutions)
Slide 10: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 10 Contract Development and Manufacturing Organization Business Consistent growth over the years – FY11 to FY21 Addressing near term pandemic induced challenges (In INR Crore) (In INR Crore) 13% CAGR 1,710 3,616 3,154 2,783 1,531 2,
Slide 11: Deep Development Project Pipeline and Growth Oriented Capex to drive growth
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 11 Deep Development Project Pipeline and Growth Oriented Capex to drive growth High proportion of commercial revenues and a deep pipeline of development projects across multiple phases FY22 Revenue by Services Pre-Clinical Phase I P
Slide 12: Integration of Recent Acquisitions on Track
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 12 Integration of Recent Acquisitions on Track Capacity expansion through continued investments in acquired entities Hemmo Pharmaceuticals Acquired 100% stake in Hemmo Pharmaceuticals, enabling expansion into Peptide API • Made addi
Slide 13: Attracting Customers with Differentiated Offerings and Integrated Services
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 13 Attracting Customers with Differentiated Offerings and Integrated Services Integrating services: Discovery - Clinical Development - Commercialization Preclinical Phase 1 Phase 2 Phase 3 Launch Off-patent Commercial CRO Developmen
Slide 14: Superior Value Proposition to Win and Retain Customers
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 14 Superior Value Proposition to Win and Retain Customers Strong Quality & Compliance Service Offerings Across Track Record the Lifecycle Geographically Diverse Differentiated Capabilities Footprint Value Proposition Patient & Custo
Slide 15: Complex Hospital Generics (Piramal Critical Care)
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 15 Complex Hospital Generics (Piramal Critical Care)
Slide 16: Complex Hospital Generics Business
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 16 Complex Hospital Generics Business Key Business Highlights Revenue growth in Q2 FY2023 (In INR Crore) Inhalation Anesthesia Strong Inhalation Anesthesia (IA) sales in the US with continued volume growth driving market share gai
Slide 17: Differentiated Portfolio with High Entry Barriers and Attractive End Market Dynamics
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 17 Differentiated Portfolio with High Entry Barriers and Attractive End Market Dynamics Inhalation Anesthesia Intrathecal Therapy High entry barriers due to need for specific vaporizers for High entry barriers due to the complexity
Slide 18: Differentiated Portfolio with High Entry Barriers and Attractive End Market Dynamics
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 18 Differentiated Portfolio with High Entry Barriers and Attractive End Market Dynamics Injectable Anaesthesia and Pain Management Other Products Fentanyl, Sufentanil, Alfentanil, Product Portfolio Piritramide, Etomidate Marketed
Slide 19: Key Differentiators Enabling Growth
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 19 Key Differentiators Enabling Growth Differentiated Portfolio with Commercial Presence in High Entry Barriers over 100 Countries Key Vertically Integrated Differentiators Strong Pipeline in Niche Manufacturing Capabilities Enablin
Slide 20: India Consumer Healthcare (Consumer Products Division)
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 20 India Consumer Healthcare (Consumer Products Division)
Slide 21: India Consumer Healthcare Business
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 21 India Consumer Healthcare Business Key Business Highlights Revenue growth in Q2 FY2023 (In INR Crore) New product launches 10 new products and 11 new SKUs launched in H1FY23 227 192 Power Brands Q2 FY22 Q2 FY23 Power Brands –
Slide 22: Diversified Portfolio of Attractive Brands, Including Power Brands
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 22 Diversified Portfolio of Attractive Brands, Including Power Brands Analgesics Skin care VMS Women’s health Digestives Kids wellness Health & Hygiene Lacto Calamine i-pill, i-know Saridon Supradyn Littles Oil Control Lotion, Contr
Slide 23: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 23 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Kareena Kapoor Priyanka Mohan Sourav Ganguly Amyra Dastur Ajay Devgan i-pill Daily Little’s Lacto - S
Slide 24: Well Established Commercial Infrastructure with Multi-channel Distribution Strategy
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 24 Well Established Commercial Infrastructure with Multi-channel Distribution Strategy Wide coverage across general trade, chemist and toy shops Strengthening presence across alternate channels Indirect Wholesale coverage (~8,000 wh
Slide 25: Piramal Pharma's D2C Platform – Wellify.in
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 25 Piramal Pharma’s D2C Platform – Wellify.in Introduced direct-to-consumer platform Wellify.in With the launch of inhouse D2C platform, Wellify.in, the company is looking at • Bolstering its e-commerce capabilities • Reaching out t
Slide 26: Allergan JV (India Ophthalmology Formulations)
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 26 Allergan JV (India Ophthalmology Formulations)
Slide 27: Strategic Ophthalmology JV with a #1 Position in the Domestic Market
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 27 Strategic Ophthalmology JV with a #1 Position in the Domestic Market Allergan India Private Limited Key highlights of the JV The JV is the leader in the eye care segment in India *now AbbVie #1 in Glaucoma (23% market share)
Slide 28: Key Strategic Priorities
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 28 Key Strategic Priorities
Slide 29: Key Strategic Priorities
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 29 Key Strategic Priorities 1 Delivering consistent revenue growth and improving profitability 2 Pursuing organic and inorganic growth opportunities leveraging fresh capital Track record of building scalable Capacity expansion acr
Slide 30: Annexures
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 30 Annexures
Slide 31: Explanation on financial statement
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 31 Explanation on financial statement Note explaining why Q2FY23 financials are strictly not comparable to Q2FY22 and Q1FY23. Similarly, H1FY23 financials are also not strictly comparable to H1FY22 The Hon’ble NCLT, on 12th Aug’22,
Slide 32: Consolidated Financials Highlights – Profit & Loss Statement
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 32 Consolidated Financials Highlights – Profit & Loss Statement To arrive at comparable financials the below adjustments have been made in the following quarter and half year: Q1FY23 & H1FY23 – Excluded one-time, non-recurring impac
Slide 33: Consolidated Financials Highlights – Balance Sheet
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 33 Consolidated Financials Highlights – Balance Sheet (In INR Crores) Key Balance Sheet Items 30-Sep-22 31-Mar-22 Total Equity 6,672 6,697 Net Debt 4,385 3,694 Deferred Consideration 90 90 Total 11,148 10,481 Net Fixed Assets 8,577
Slide 34: Dial-in details for Q2 and H1 FY2023 Earnings Conference Call
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 34 Dial-in details for Q2 and H1 FY2023 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 5:00 PM IST 1 800 120 1221(Toll free number) USA – 7:30 AM Toll fre
Slide 35: For Investor Queries:
Piramal Pharma Limited – Q2 and H1 FY2023 Results Presentation Page 35 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090